ood morning, everyone. STAT reporter Rebecca Robbins here, filling in to serve up your breakfast buffet of headlines from the world of pharma. Another week has nearly come and gone, which means it’s time to daydream about the weekend and its assorted respites. Do be certain to relax, and try to have fun, and stay safe, whatever it is you end up doing. Until then, send us a note if you hear anything that warrants a spot in these digital pages.

Lawmakers have some questions for Merck (MRK) about how a cyberattack in June roiled its operations, including whether it hit the company’s supplies of the hepatitis B vaccine, Endpoints tells us. In a letter to Merck sent this week, the House Committee on Energy and Commerce requested a formal briefing from the company by October 4.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.